Zhejiang Huahai Pharmaceutical Co.,Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has entered into a global research collaboration and licensing agreement with Almirall, S.A. The partnership focuses on developing monoclonal antibody candidate drugs targeting novel mechanisms for multiple potential indications, including medical dermatology. Under the agreement, Huatai retains rights to develop and commercialize the program and resulting products in China, while ALM holds exclusive global development and commercialization rights outside of China. Huatai will conduct research using its innovative R&D platform through the proof-of-concept clinical stage. ALM will make an upfront payment to Huatai, along with development and commercial milestone payments totaling up to $340 million, plus tiered royalties.